Top entities: Rhythm Pharmaceuticals, Kuehn Law, Justin Kuehn, United States — Food and Drug Administration.

What category does this event fall under?

Business — classified as shareholder lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business shareholder lawsuit

Inovio_Pharmaceuticals faces shareholder lawsuit

Q: When did this event occur?

First reported Jun 01, 2026; last updated Jun 04, 2026.

Q: What is the market impact?

General. The market is impacted by the potential for a class-action lawsuit against Rhythm Pharmaceuticals, which could lead to significant financial penalties and a decline in its stock price.

Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 04, 2026

Sentiment

-20

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is impacted by the potential for a class-action lawsuit against Rhythm Pharmaceuticals, which could lead to significant financial penalties and a decline in its stock price. This event also highlights regulatory scrutiny in the pharmaceutical industry, potentially affecting investor confidence in companies with similar product development timelines.

Pharmaceuticals Biotechnology Legal Services

Event Summary

Kuehn Law, a shareholder litigation law firm, is investigating officers and directors of Rhythm Pharmaceuticals for allegedly breaching their fiduciary duties. A federal securities lawsuit claims that Rhythm Pharmaceuticals insiders misrepresented or failed to disclose critical information, including deficient manufacturing for its CELLECTRA device, unlikelihood of submitting the INO-3107 BLA to the United States — Food and Drug Administration by the second half of 2024, and insufficient justification for accelerated approval or priority review. These alleged misrepresentations overstated the regulatory and commercial prospects of INO-3107. Kuehn Law is encouraging Rhythm Pharmaceuticals shareholders who purchased prior to October 10, 2023, to contact Justin Kuehn for participation in the lawsuit.

Entities Involved

stock

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is facing a federal securities lawsuit alleging that its officers and directors breached fiduciary duties by misrepresenting or failing to disclose critical information regarding its CELLECTRA device and INO-3107 BLA submission.

Importance 100.0 Sentiment -30.0

oth

Kuehn Law

Kuehn Law is a shareholder litigation law firm investigating Rhythm Pharmaceuticals for alleged breaches of fiduciary duties and is encouraging investors to contact them regarding the lawsuit.

Importance 80.0 Sentiment 10.0

per

Justin Kuehn

Justin Kuehn is an attorney at Kuehn Law, leading the investigation into Rhythm Pharmaceuticals and serving as the primary contact for affected shareholders.

Importance 60.0 Sentiment 10.0

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration is relevant as the regulatory body to which Rhythm Pharmaceuticals was expected to submit its INO-3107 BLA, and whose approval prospects were allegedly overstated.

Importance 40.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard